NADER EL-MALLAWANY to Immunotherapy
This is a "connection" page, showing publications NADER EL-MALLAWANY has written about Immunotherapy.
Connection Strength
0.147
-
Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2015 Feb; 13(2):113-23.
Score: 0.047
-
Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S6-13.
Score: 0.046
-
Long-term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy. Bone Marrow Transplant. 2011 May; 46(5):759-61.
Score: 0.034
-
Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2023 01; 64(1):234-237.
Score: 0.020